David Stock

3.1k total citations · 4 hit papers
48 papers, 2.2k citations indexed

About

David Stock is a scholar working on Infectious Diseases, Psychiatry and Mental health and Virology. According to data from OpenAlex, David Stock has authored 48 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 12 papers in Psychiatry and Mental health and 10 papers in Virology. Recurrent topics in David Stock's work include HIV/AIDS drug development and treatment (12 papers), Migraine and Headache Studies (11 papers) and HIV Research and Treatment (10 papers). David Stock is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), Migraine and Headache Studies (11 papers) and HIV Research and Treatment (10 papers). David Stock collaborates with scholars based in United States, United Kingdom and Peru. David Stock's co-authors include Peter J. Goadsby, Robert Croop, Vladimir Coric, Richard B. Lipton, Elyse Stock, Charles M. Conway, Micaela Forshaw, Tanya Fischer, Ronald N. Marcus and George Manos and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

David Stock

43 papers receiving 2.1k citations

Hit Papers

Efficacy, safety, and tol... 2019 2026 2021 2023 2019 2019 2020 2023 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
    2019 276 citations Robert Croop, Peter J. Goadsby et al. The Lancet profile →
  2. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
    2019 265 citations Richard B. Lipton, Robert Croop et al. profile →
  3. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
    2020 233 citations Robert Croop, Richard B. Lipton et al. The Lancet profile →
  4. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
    2023 85 citations Richard B. Lipton, Robert Croop et al. The Lancet Neurology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David Stock 1.1k 697 432 417 350 48 2.2k
David B. Clifford 280 0.2× 249 0.4× 1.3k 3.0× 584 1.4× 792 2.3× 58 3.4k
Paul Dyken 345 0.3× 93 0.1× 712 1.6× 263 0.6× 69 0.2× 58 2.1k
Laura E. Pope 213 0.2× 125 0.2× 129 0.3× 64 0.2× 33 0.1× 42 1.6k
Padma Maruvada 193 0.2× 95 0.1× 321 0.7× 127 0.3× 25 0.1× 67 2.3k
Annie Lannuzel 72 0.1× 73 0.1× 392 0.9× 310 0.7× 155 0.4× 65 2.4k
Dawn McGuire 96 0.1× 102 0.1× 535 1.2× 51 0.1× 78 0.2× 37 1.9k
Akiko Kikuchi 168 0.1× 144 0.2× 118 0.3× 67 0.2× 20 0.1× 108 1.8k
J.G. Gobert 520 0.5× 35 0.1× 117 0.3× 196 0.5× 27 0.1× 53 1.4k
P. Donatsch 75 0.1× 63 0.1× 257 0.6× 88 0.2× 80 0.2× 45 2.2k
Yuyuan Huang 332 0.3× 65 0.1× 485 1.1× 62 0.1× 18 0.1× 124 1.6k

Countries citing papers authored by David Stock

Since Specialization
Citations

This map shows the geographic impact of David Stock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Stock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Stock more than expected).

Fields of papers citing papers by David Stock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Stock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Stock. The network helps show where David Stock may publish in the future.

Co-authorship network of co-authors of David Stock

This figure shows the co-authorship network connecting the top 25 collaborators of David Stock. A scholar is included among the top collaborators of David Stock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Stock. David Stock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vu, Khanh Dang, et al.. (2025). Calcitonin Gene-Related Peptide Inhibitor Use in 2018–2023: A Retrospective Cohort Study Across Six Canadian Provinces. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 1–10.
2.
Pataky, Reka, Maud Marques, Karen Gambaro, et al.. (2024). Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada. Current Oncology. 31(6). 3591–3602. 1 indexed citations
3.
4.
Lipton, Richard B., Robert Croop, David Stock, et al.. (2023). Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. The Lancet Neurology. 22(3). 209–217. 85 indexed citations breakdown →
5.
6.
Croop, Robert, Richard B. Lipton, David Kudrow, et al.. (2020). Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet. 397(10268). 51–60. 233 indexed citations breakdown →
7.
Croop, Robert, Peter J. Goadsby, David Stock, et al.. (2019). Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet. 394(10200). 737–745. 276 indexed citations breakdown →
8.
9.
Lalezari, Jacob, Gulam Latiff, Cynthia Brinson, et al.. (2015). Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. The Lancet HIV. 2(10). e427–e437. 50 indexed citations
10.
Gupta, Samir K., Grace A. McComsey, Juan Echevarría, et al.. (2015). Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. The Lancet HIV. 3(1). e13–e22. 9 indexed citations
11.
Lalezari, Jacob, Gulam Latiff, Cynthia Brinson, et al.. (2014). Safety profile of HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 analysis. Journal of the International AIDS Society. 17(4S3). 19530–19530. 4 indexed citations
12.
Brinson, Cynthia, Jacob Lalezari, Melanie Thompson, et al.. (2014). HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 sub‐group analysis. Journal of the International AIDS Society. 17(4S3). 19529–19529. 2 indexed citations
13.
Marcus, Ronald N., Peter J. Goadsby, David W. Dodick, et al.. (2013). BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 34(2). 114–125. 225 indexed citations
14.
Stock, David, et al.. (2010). Large sample inference for an assay quality measure used in high‐throughput screening. Pharmaceutical Statistics. 10(3). 227–231. 1 indexed citations
15.
Stock, David, John E. Leet, Lynda Cook, et al.. (2009). Best Practices in Compound Management for Preserving Compound Integrity and Accurately Providing Samples for Assays. SLAS DISCOVERY. 14(5). 476–484. 21 indexed citations
16.
Heimke, G. & David Stock. (2008). Zur Frage postoperativer Schmerzen bei zementfreien Hüftschaftprothesen. Zeitschrift für Orthopädie und ihre Grenzgebiete. 124(5). 643–645.
17.
Lindner, Mark D., John B. Hogan, R. M. Krause, et al.. (2006). Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice. Behavioural Brain Research. 173(1). 62–75. 17 indexed citations
18.
Lindner, Mark D., Clotilde Bourin, Ping Chen, et al.. (2006). Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.. Experimental and Clinical Psychopharmacology. 14(1). 42–51. 14 indexed citations
19.
Bronson, Joanne J., Stanley V. D’Andrea, Milind Deshpande, et al.. (2000). 4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB. Bioorganic & Medicinal Chemistry Letters. 10(8). 715–717. 201 indexed citations
20.
Davids, Keith, et al.. (1999). Interacting Constraints and the Emergence of Postural Behavior in ACL-Deficient Subjects. Journal of Motor Behavior. 31(4). 358–366. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David B. Clifford Breakdown of academic impact, for papers by Paul Dyken Breakdown of academic impact, for papers by Laura E. Pope Breakdown of academic impact, for papers by Padma Maruvada Breakdown of academic impact, for papers by Annie Lannuzel Breakdown of academic impact, for papers by Dawn McGuire Breakdown of academic impact, for papers by Akiko Kikuchi Breakdown of academic impact, for papers by J.G. Gobert Breakdown of academic impact, for papers by P. Donatsch Breakdown of academic impact, for papers by Yuyuan Huang
Rankless by CCL
2026